<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC10877805</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC10877805.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">10877805</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">10877805</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">38378607</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1186/s13195-024-01407-w</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">1407</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic data of participants along AD continuum</table-caption><table-wrap-foot>The log-transformed WMH volume is used to represent the burden of white matter hyperintensity (WMH)The choroid volume (mm3)/TIV (ml)*103 is used to represent choroid plexus volumeCN Cognitive normal, MCI Mild cognitive impairment, AD Alzheimer’s disease, TIV Total intracranial volume, WMH White matter hyperintensity, PVS Perivascular spaceaOne CN − and 4 CN + participants without the information of APOE status</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic data of participants along AD continuum</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><bold>CN A − (</bold><bold><italic toggle="yes">N</italic></bold><bold> = 40)</bold></th><th align="left" colspan="1" rowspan="1"><bold>CN A + (</bold><bold><italic toggle="yes">N</italic></bold><bold> = 48)</bold></th><th align="left" colspan="1" rowspan="1"><bold>MCI A + (</bold><bold><italic toggle="yes">N</italic></bold><bold> = 26)</bold></th><th align="left" colspan="1" rowspan="1"><bold>AD A + (</bold><bold><italic toggle="yes">N</italic></bold><bold> = 19)</bold></th><th align="left" colspan="1" rowspan="1"><bold><italic toggle="yes">p</italic></bold></th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1"><bold>Demographics</bold></td></tr><tr><td align="left" colspan="1" rowspan="1"> Age (years)</td><td align="left" colspan="1" rowspan="1">75.2 ± 8.4</td><td align="left" colspan="1" rowspan="1">74.9 ± 7.5</td><td align="left" colspan="1" rowspan="1">75.4 ± 9.2</td><td align="left" colspan="1" rowspan="1">75.7 ± 9.6</td><td align="left" colspan="1" rowspan="1">0.123</td></tr><tr><td align="left" colspan="1" rowspan="1"> Male, <italic toggle="yes">N</italic> (%)</td><td align="left" colspan="1" rowspan="1">17 (42.5%)</td><td align="left" colspan="1" rowspan="1">17 (35.4%)</td><td align="left" colspan="1" rowspan="1">7 (26.9%)</td><td align="left" colspan="1" rowspan="1">9 (47.4%)</td><td align="left" colspan="1" rowspan="1">0.367</td></tr><tr><td align="left" colspan="1" rowspan="1"> Education (years)</td><td align="left" colspan="1" rowspan="1">16.1 ± 2.4</td><td align="left" colspan="1" rowspan="1">16.6 ± 2.4</td><td align="left" colspan="1" rowspan="1">15.8 ± 2.3</td><td align="left" colspan="1" rowspan="1">15.3 ± 2.4</td><td align="left" colspan="1" rowspan="1">0.144</td></tr><tr><td align="left" colspan="1" rowspan="1"> APOE ε4, <italic toggle="yes">N</italic> (%)</td><td align="left" colspan="1" rowspan="1">9 (23.1%)<sup>a</sup></td><td align="left" colspan="1" rowspan="1">22 (45.8%)<sup>a</sup></td><td align="left" colspan="1" rowspan="1">15 (57.7%)</td><td align="left" colspan="1" rowspan="1">11 (57.9%)</td><td align="left" colspan="1" rowspan="1">0.763</td></tr><tr><td align="left" colspan="6" rowspan="1"><bold>Vascular risk factors</bold></td></tr><tr><td align="left" colspan="1" rowspan="1"> Hypertension, <italic toggle="yes">N</italic> (%)</td><td align="left" colspan="1" rowspan="1">14 (35.0%)</td><td align="left" colspan="1" rowspan="1">22 (45.8%)</td><td align="left" colspan="1" rowspan="1">13 (50.0%)</td><td align="left" colspan="1" rowspan="1">8 (44.4%)</td><td align="left" colspan="1" rowspan="1">0.630</td></tr><tr><td align="left" colspan="1" rowspan="1"> Diabetes, <italic toggle="yes">N</italic> (%)</td><td align="left" colspan="1" rowspan="1">3 (7.5%)</td><td align="left" colspan="1" rowspan="1">6 (12.5%)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0.128</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hyperlipidemia, <italic toggle="yes">N</italic> (%)</td><td align="left" colspan="1" rowspan="1">16 (40%)</td><td align="left" colspan="1" rowspan="1">26 (54.2%)</td><td align="left" colspan="1" rowspan="1">12 (46.2%)</td><td align="left" colspan="1" rowspan="1">8 (44.4%)</td><td align="left" colspan="1" rowspan="1">0.608</td></tr><tr><td align="left" colspan="1" rowspan="1"> Smoking, <italic toggle="yes">N</italic> (%)</td><td align="left" colspan="1" rowspan="1">6 (15.0%)</td><td align="left" colspan="1" rowspan="1">9 (18.8%)</td><td align="left" colspan="1" rowspan="1">6 (23.1%)</td><td align="left" colspan="1" rowspan="1">1 (5.6%)</td><td align="left" colspan="1" rowspan="1">0.458</td></tr><tr><td align="left" colspan="1" rowspan="1"> Heart disease, <italic toggle="yes">N</italic> (%)</td><td align="left" colspan="1" rowspan="1">6 (15.0%)</td><td align="left" colspan="1" rowspan="1">4 (8.3%)</td><td align="left" colspan="1" rowspan="1">4 (15.4%)</td><td align="left" colspan="1" rowspan="1">3 (16.7%)</td><td align="left" colspan="1" rowspan="1">0.701</td></tr><tr><td align="left" colspan="6" rowspan="1"><bold>Imaging characteristics</bold></td></tr><tr><td align="left" colspan="1" rowspan="1"> TIV (mm<sup>3</sup>)</td><td align="left" colspan="1" rowspan="1">1483.4 ± 147.4</td><td align="left" colspan="1" rowspan="1">1461.7 ± 150.0</td><td align="left" colspan="1" rowspan="1">1457.2 ± 147.0</td><td align="left" colspan="1" rowspan="1">1467.4 ± 207.8</td><td align="left" colspan="1" rowspan="1">0.901</td></tr><tr><td align="left" colspan="1" rowspan="1"> WMH burden</td><td align="left" colspan="1" rowspan="1"> − 0.006 ± 0.505</td><td align="left" colspan="1" rowspan="1">0.391 ± 0.723</td><td align="left" colspan="1" rowspan="1">0.418 ± 0.646</td><td align="left" colspan="1" rowspan="1">0.868 ± 0.532</td><td align="left" colspan="1" rowspan="1"> &lt; 0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"> Presence of lacune, <italic toggle="yes">N</italic> (%)</td><td align="left" colspan="1" rowspan="1">2 (5%)</td><td align="left" colspan="1" rowspan="1">5 (10.4%)</td><td align="left" colspan="1" rowspan="1">2 (7.7%)</td><td align="left" colspan="1" rowspan="1">1 (5.3%)</td><td align="left" colspan="1" rowspan="1">0.781</td></tr><tr><td align="left" colspan="1" rowspan="1"> Presence of microbleed (%)</td><td align="left" colspan="1" rowspan="1">4 (10%)</td><td align="left" colspan="1" rowspan="1">3 (6.3%)</td><td align="left" colspan="1" rowspan="1">3 (11.5%)</td><td align="left" colspan="1" rowspan="1">6 (31.6%)</td><td align="left" colspan="1" rowspan="1">0.036</td></tr><tr><td align="left" colspan="1" rowspan="1"> Global Aβ burden (SUVR)</td><td align="left" colspan="1" rowspan="1">1.024 ± 0.047</td><td align="left" colspan="1" rowspan="1">1.298 ± 0.178</td><td align="left" colspan="1" rowspan="1">1.458 ± 0.201</td><td align="left" colspan="1" rowspan="1">1.417 ± 0.161</td><td align="left" colspan="1" rowspan="1"> &lt; 0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">PVS rating score</td></tr><tr><td align="left" colspan="1" rowspan="1"> Basal ganglia PVS</td><td align="left" colspan="1" rowspan="1">2.00 (2.00–3.75)</td><td align="left" colspan="1" rowspan="1">2.50 (2.00–3.00)</td><td align="left" colspan="1" rowspan="1">3.00 (1.00–3.25)</td><td align="left" colspan="1" rowspan="1">3.00 (1.00–4.00)</td><td align="left" colspan="1" rowspan="1">0.041</td></tr><tr><td align="left" colspan="1" rowspan="1"> White matter PVS</td><td align="left" colspan="1" rowspan="1">2.00 (2.00–2.75)</td><td align="left" colspan="1" rowspan="1">3.00 (2.00–3.00)</td><td align="left" colspan="1" rowspan="1">2.00 (1.75–3.00)</td><td align="left" colspan="1" rowspan="1">3.00 (2.00–3.00)</td><td align="left" colspan="1" rowspan="1">0.987</td></tr><tr><td align="left" colspan="1" rowspan="1"> Choroid plexus volume</td><td align="left" colspan="1" rowspan="1">1.085 ± 0.339</td><td align="left" colspan="1" rowspan="1">1.005 ± 0.244</td><td align="left" colspan="1" rowspan="1">1.061 ± 0.232</td><td align="left" colspan="1" rowspan="1">1.229 ± 0.225</td><td align="left" colspan="1" rowspan="1">0.029</td></tr><tr><td align="left" colspan="1" rowspan="1"> DTI-ALPS</td><td align="left" colspan="1" rowspan="1">1.355 ± 0.155</td><td align="left" colspan="1" rowspan="1">1.341 ± 0.106</td><td align="left" colspan="1" rowspan="1">1.255 ± 0.161</td><td align="left" colspan="1" rowspan="1">1.154 ± 0.184</td><td align="left" colspan="1" rowspan="1"> &lt; 0.001</td></tr></tbody></table><table-wrap-foot><p>The log-transformed WMH volume is used to represent the burden of white matter hyperintensity (WMH)</p><p>The choroid volume (mm<sup>3</sup>)/TIV (ml)*10<sup>3</sup> is used to represent choroid plexus volume</p><p><italic toggle="yes">CN </italic>Cognitive normal, <italic toggle="yes">MCI </italic>Mild cognitive impairment, <italic toggle="yes">AD </italic>Alzheimer’s disease, <italic toggle="yes">TIV </italic>Total intracranial volume, <italic toggle="yes">WMH </italic>White matter hyperintensity, <italic toggle="yes">PVS </italic>Perivascular space</p><p><sup>a</sup>One CN − and 4 CN + participants without the information of APOE status</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic data of participants along AD continuum</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">CN A − (N = 40)</th><th align="left">CN A + (N = 48)</th><th align="left">MCI A + (N = 26)</th><th align="left">AD A + (N = 19)</th><th align="left">p</th></tr></thead><tbody><tr><td align="left" colspan="6">Demographics</td></tr><tr><td align="left"> Age (years)</td><td align="left">75.2 ± 8.4</td><td align="left">74.9 ± 7.5</td><td align="left">75.4 ± 9.2</td><td align="left">75.7 ± 9.6</td><td align="left">0.123</td></tr><tr><td align="left"> Male, N (%)</td><td align="left">17 (42.5%)</td><td align="left">17 (35.4%)</td><td align="left">7 (26.9%)</td><td align="left">9 (47.4%)</td><td align="left">0.367</td></tr><tr><td align="left"> Education (years)</td><td align="left">16.1 ± 2.4</td><td align="left">16.6 ± 2.4</td><td align="left">15.8 ± 2.3</td><td align="left">15.3 ± 2.4</td><td align="left">0.144</td></tr><tr><td align="left"> APOE ε4, N (%)</td><td align="left">9 (23.1%)a</td><td align="left">22 (45.8%)a</td><td align="left">15 (57.7%)</td><td align="left">11 (57.9%)</td><td align="left">0.763</td></tr><tr><td align="left" colspan="6">Vascular risk factors</td></tr><tr><td align="left"> Hypertension, N (%)</td><td align="left">14 (35.0%)</td><td align="left">22 (45.8%)</td><td align="left">13 (50.0%)</td><td align="left">8 (44.4%)</td><td align="left">0.630</td></tr><tr><td align="left"> Diabetes, N (%)</td><td align="left">3 (7.5%)</td><td align="left">6 (12.5%)</td><td align="left">0</td><td align="left">0</td><td align="left">0.128</td></tr><tr><td align="left"> Hyperlipidemia, N (%)</td><td align="left">16 (40%)</td><td align="left">26 (54.2%)</td><td align="left">12 (46.2%)</td><td align="left">8 (44.4%)</td><td align="left">0.608</td></tr><tr><td align="left"> Smoking, N (%)</td><td align="left">6 (15.0%)</td><td align="left">9 (18.8%)</td><td align="left">6 (23.1%)</td><td align="left">1 (5.6%)</td><td align="left">0.458</td></tr><tr><td align="left"> Heart disease, N (%)</td><td align="left">6 (15.0%)</td><td align="left">4 (8.3%)</td><td align="left">4 (15.4%)</td><td align="left">3 (16.7%)</td><td align="left">0.701</td></tr><tr><td align="left" colspan="6">Imaging characteristics</td></tr><tr><td align="left"> TIV (mm3)</td><td align="left">1483.4 ± 147.4</td><td align="left">1461.7 ± 150.0</td><td align="left">1457.2 ± 147.0</td><td align="left">1467.4 ± 207.8</td><td align="left">0.901</td></tr><tr><td align="left"> WMH burden</td><td align="left"> − 0.006 ± 0.505</td><td align="left">0.391 ± 0.723</td><td align="left">0.418 ± 0.646</td><td align="left">0.868 ± 0.532</td><td align="left"> &lt; 0.001</td></tr><tr><td align="left"> Presence of lacune, N (%)</td><td align="left">2 (5%)</td><td align="left">5 (10.4%)</td><td align="left">2 (7.7%)</td><td align="left">1 (5.3%)</td><td align="left">0.781</td></tr><tr><td align="left"> Presence of microbleed (%)</td><td align="left">4 (10%)</td><td align="left">3 (6.3%)</td><td align="left">3 (11.5%)</td><td align="left">6 (31.6%)</td><td align="left">0.036</td></tr><tr><td align="left"> Global Aβ burden (SUVR)</td><td align="left">1.024 ± 0.047</td><td align="left">1.298 ± 0.178</td><td align="left">1.458 ± 0.201</td><td align="left">1.417 ± 0.161</td><td align="left"> &lt; 0.001</td></tr><tr><td align="left" colspan="6">PVS rating score</td></tr><tr><td align="left"> Basal ganglia PVS</td><td align="left">2.00 (2.00–3.75)</td><td align="left">2.50 (2.00–3.00)</td><td align="left">3.00 (1.00–3.25)</td><td align="left">3.00 (1.00–4.00)</td><td align="left">0.041</td></tr><tr><td align="left"> White matter PVS</td><td align="left">2.00 (2.00–2.75)</td><td align="left">3.00 (2.00–3.00)</td><td align="left">2.00 (1.75–3.00)</td><td align="left">3.00 (2.00–3.00)</td><td align="left">0.987</td></tr><tr><td align="left"> Choroid plexus volume</td><td align="left">1.085 ± 0.339</td><td align="left">1.005 ± 0.244</td><td align="left">1.061 ± 0.232</td><td align="left">1.229 ± 0.225</td><td align="left">0.029</td></tr><tr><td align="left"> DTI-ALPS</td><td align="left">1.355 ± 0.155</td><td align="left">1.341 ± 0.106</td><td align="left">1.255 ± 0.161</td><td align="left">1.154 ± 0.184</td><td align="left"> &lt; 0.001</td></tr></tbody></table></div>The log-transformed WMH volume is used to represent the burden of white matter hyperintensity (WMH)The choroid volume (mm3)/TIV (ml)*103 is used to represent choroid plexus volumeCN Cognitive normal, MCI Mild cognitive impairment, AD Alzheimer’s disease, TIV Total intracranial volume, WMH White matter hyperintensity, PVS Perivascular spaceaOne CN − and 4 CN + participants without the information of APOE status</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>The association of basal ganglia PVS and white matter PVS with WMH burden and Aβ in amyloid positive participants</table-caption><table-wrap-foot>Model 1: age, sex, and TIV were included as covariatesModel 2: age, sex, TIV, and APOE status were included as covariatesTIV Total intracranial volume, WMH White matter hyperintensity, PVS Perivascular space</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>The association of basal ganglia PVS and white matter PVS with WMH burden and Aβ in amyloid positive participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Basal ganglia PVS</th><th align="left" colspan="2" rowspan="1">White matter PVS</th></tr><tr><th align="left" colspan="1" rowspan="1"><italic toggle="yes">β</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">β</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Model 1</td></tr><tr><td align="left" colspan="1" rowspan="1"> Aβ</td><td align="left" colspan="1" rowspan="1"> − 1.238</td><td align="left" colspan="1" rowspan="1">0.347</td><td align="left" colspan="1" rowspan="1"> − 0.867</td><td align="left" colspan="1" rowspan="1">0.494</td></tr><tr><td align="left" colspan="1" rowspan="1"> WMH burden</td><td align="left" colspan="1" rowspan="1">0.542</td><td align="left" colspan="1" rowspan="1">0.173</td><td align="left" colspan="1" rowspan="1">0.054</td><td align="left" colspan="1" rowspan="1">0.889</td></tr><tr><td align="left" colspan="5" rowspan="1">Model 2</td></tr><tr><td align="left" colspan="1" rowspan="1"> Aβ</td><td align="left" colspan="1" rowspan="1"> − 1.212</td><td align="left" colspan="1" rowspan="1">0.379</td><td align="left" colspan="1" rowspan="1"> − 0.754</td><td align="left" colspan="1" rowspan="1">0.575</td></tr><tr><td align="left" colspan="1" rowspan="1"> WMH burden</td><td align="left" colspan="1" rowspan="1">0.489</td><td align="left" colspan="1" rowspan="1">0.225</td><td align="left" colspan="1" rowspan="1"> − 0.054</td><td align="left" colspan="1" rowspan="1">0.890</td></tr></tbody></table><table-wrap-foot><p>Model 1: age, sex, and TIV were included as covariates</p><p>Model 2: age, sex, TIV, and APOE status were included as covariates</p><p><italic toggle="yes">TIV </italic>Total intracranial volume, <italic toggle="yes">WMH </italic>White matter hyperintensity, <italic toggle="yes">PVS </italic>Perivascular space</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">The association of basal ganglia PVS and white matter PVS with WMH burden and Aβ in amyloid positive participants</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Basal ganglia PVS</th><th align="left" colspan="2">White matter PVS</th></tr><tr><th align="left">β</th><th align="left">p</th><th align="left">β</th><th align="left">p</th></tr></thead><tbody><tr><td align="left" colspan="5">Model 1</td></tr><tr><td align="left"> Aβ</td><td align="left"> − 1.238</td><td align="left">0.347</td><td align="left"> − 0.867</td><td align="left">0.494</td></tr><tr><td align="left"> WMH burden</td><td align="left">0.542</td><td align="left">0.173</td><td align="left">0.054</td><td align="left">0.889</td></tr><tr><td align="left" colspan="5">Model 2</td></tr><tr><td align="left"> Aβ</td><td align="left"> − 1.212</td><td align="left">0.379</td><td align="left"> − 0.754</td><td align="left">0.575</td></tr><tr><td align="left"> WMH burden</td><td align="left">0.489</td><td align="left">0.225</td><td align="left"> − 0.054</td><td align="left">0.890</td></tr></tbody></table></div>Model 1: age, sex, and TIV were included as covariatesModel 2: age, sex, TIV, and APOE status were included as covariatesTIV Total intracranial volume, WMH White matter hyperintensity, PVS Perivascular space</transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>The association between glymphatic markers and cognitive domains</table-caption><table-wrap-foot>PVS Perivascular space, FDR False discovery rate</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>The association between glymphatic markers and cognitive domains</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">DTI-ALPS</th><th align="left" colspan="2" rowspan="1">Choroid plexus</th><th align="left" colspan="2" rowspan="1">Basal ganglia PVS</th><th align="left" colspan="2" rowspan="1">White matter PVS</th></tr><tr><th align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic></th><th align="left" colspan="1" rowspan="1">FDR-p</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic></th><th align="left" colspan="1" rowspan="1">FDR-p</th><th align="left" colspan="1" rowspan="1">Rho</th><th align="left" colspan="1" rowspan="1">FDR-p</th><th align="left" colspan="1" rowspan="1">Rho</th><th align="left" colspan="1" rowspan="1">FDR-p</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Memory</td><td align="left" colspan="1" rowspan="1">0.470</td><td align="left" colspan="1" rowspan="1"> &lt; 0.001</td><td align="left" colspan="1" rowspan="1"> − 0.315</td><td align="left" colspan="1" rowspan="1">0.007</td><td align="left" colspan="1" rowspan="1">0.060</td><td align="left" colspan="1" rowspan="1">0.704</td><td align="left" colspan="1" rowspan="1">0.054</td><td align="left" colspan="1" rowspan="1">0.788</td></tr><tr><td align="left" colspan="1" rowspan="1">Executive function</td><td align="left" colspan="1" rowspan="1">0.358</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1"> − 0.321</td><td align="left" colspan="1" rowspan="1">0.007</td><td align="left" colspan="1" rowspan="1"> − 0.042</td><td align="left" colspan="1" rowspan="1">0.704</td><td align="left" colspan="1" rowspan="1">0.114</td><td align="left" colspan="1" rowspan="1">0.601</td></tr><tr><td align="left" colspan="1" rowspan="1">Visual-spatial</td><td align="left" colspan="1" rowspan="1">0.223</td><td align="left" colspan="1" rowspan="1">0.040</td><td align="left" colspan="1" rowspan="1"> − 0.233</td><td align="left" colspan="1" rowspan="1">0.031</td><td align="left" colspan="1" rowspan="1"> − 0.076</td><td align="left" colspan="1" rowspan="1">0.704</td><td align="left" colspan="1" rowspan="1"> − 0.030</td><td align="left" colspan="1" rowspan="1">0.261</td></tr><tr><td align="left" colspan="1" rowspan="1">Language</td><td align="left" colspan="1" rowspan="1">0.419</td><td align="left" colspan="1" rowspan="1"> &lt; 0.001</td><td align="left" colspan="1" rowspan="1"> − 0.261</td><td align="left" colspan="1" rowspan="1">0.021</td><td align="left" colspan="1" rowspan="1"> − 0.082</td><td align="left" colspan="1" rowspan="1">0.704</td><td align="left" colspan="1" rowspan="1">0.201</td><td align="left" colspan="1" rowspan="1">0.788</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">PVS </italic>Perivascular space, <italic toggle="yes">FDR </italic>False discovery rate</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">The association between glymphatic markers and cognitive domains</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">DTI-ALPS</th><th align="left" colspan="2">Choroid plexus</th><th align="left" colspan="2">Basal ganglia PVS</th><th align="left" colspan="2">White matter PVS</th></tr><tr><th align="left">r</th><th align="left">FDR-p</th><th align="left">r</th><th align="left">FDR-p</th><th align="left">Rho</th><th align="left">FDR-p</th><th align="left">Rho</th><th align="left">FDR-p</th></tr></thead><tbody><tr><td align="left">Memory</td><td align="left">0.470</td><td align="left"> &lt; 0.001</td><td align="left"> − 0.315</td><td align="left">0.007</td><td align="left">0.060</td><td align="left">0.704</td><td align="left">0.054</td><td align="left">0.788</td></tr><tr><td align="left">Executive function</td><td align="left">0.358</td><td align="left">0.001</td><td align="left"> − 0.321</td><td align="left">0.007</td><td align="left"> − 0.042</td><td align="left">0.704</td><td align="left">0.114</td><td align="left">0.601</td></tr><tr><td align="left">Visual-spatial</td><td align="left">0.223</td><td align="left">0.040</td><td align="left"> − 0.233</td><td align="left">0.031</td><td align="left"> − 0.076</td><td align="left">0.704</td><td align="left"> − 0.030</td><td align="left">0.261</td></tr><tr><td align="left">Language</td><td align="left">0.419</td><td align="left"> &lt; 0.001</td><td align="left"> − 0.261</td><td align="left">0.021</td><td align="left"> − 0.082</td><td align="left">0.704</td><td align="left">0.201</td><td align="left">0.788</td></tr></tbody></table></div>PVS Perivascular space, FDR False discovery rate</transformed-table></extracted-table></extracted-tables-set>